阿替普酶静脉溶栓治疗轻型缺血性卒中的效果分析  

Effect of Alteplase Intravenous Thrombolysis on Mild Ischemic Stroke

作　　者：宋成 荆艳[1] 魏云[1] SONG Cheng;JING Yan;WEI Yun(Department of Neurology,Tianjin Permanent Hospital,Tianjin 300450,China)

机构地区：[1]天津市永久医院神经内科,天津300450

出　　处：《中国药物滥用防治杂志》2024年第10期1870-1872,共3页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:探究阿替普酶静脉溶栓治疗轻型缺血性卒中的作用。方法:选取天津市环湖医院2018年9月—2019年9月收治的96例轻型缺血性卒中患者,随机分为对照组47例和观察组49例。对照组不使用溶栓治疗,观察组使用阿替普酶静脉溶栓治疗,比较两组NIHSS评分、预后良好率及安全性。结果:治疗后,观察组NIHSS评分低于对照组(P<0.05);观察组预后良好率为95.92%,高于对照组的53.19%(P<0.05);两组均未发生严重不良反应。结论:阿替普酶静脉溶栓治疗轻型缺血性卒中患者的效果良好,可减轻患者的神经功能缺损程度,改善患者日常生活状态,且安全性较高。Objective:To explore the effect of intravenous thrombolysis with alteplase in the treatment of mild ischemic stroke.Methods:A total of 96 patients with mild ischemic stroke admitted to Tianjin Huanhu Hospital from September 2018 to September 2019 were randomly divided into control group(47 patients)and observation group(49 patients).The control group was not treated with thrombolytic therapy,and the observation group was treated with alteplase intravenous thrombolytic therapy.The NIHSS score,good prognosis rate and safety were compared between the two groups.Results:After treatment,the NIHSS score of the observation group was lower than that of the control group(P<0.05).The good prognosis rate of the observation group was 95.92%,which was higher than 53.19%of the control group(P<0.05).No serious adverse reactions occurred in both groups.Conclusion:Alteplase intravenous thrombolysis is effective in the treatment of patients with mild ischemic stroke,which can reduce the degree of neurological deficits and improve the daily living status of patients,and has high safety.

关 键 词：阿替普酶 静脉溶栓 轻型缺血性卒中 

分 类 号：R743.3[医药卫生—神经病学与精神病学]